Communiqués LifeMD, Inc.

Actions

LFMD

US53216B1044

Equipement et technologie médicale avancés

Temps réel estimé Cboe BZX Autres places de cotation 21:42:32 14/07/2026			Varia. 5j.	Varia. 1 janv.
4,540 ^USD	-4,62%		-7,38%	+32,55%

22/06	LifeMD, Inc. et Antares Pharma, Inc. lancent un programme de paiement direct pour le traitement XYOSTED (énanthate de testostérone) en injection	CI
01/06	LifeMD, Inc. annonce la nomination d'Umesh Sripad au poste de Chief Technology Officer, à compter du 1er juin 2026	CI

Communiqués

24/06	Best GLP-1 Medical Weight Loss Clinics in 2026 \| Good Life Health	AQ
23/06	LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock	AQ
22/06	LifeMD Announces Exclusive Collaboration to Launch Direct-to-Patient Self-Pay Program for XYOSTED® (testosterone enanthate) Injection	AQ
01/06	LifeMD Appoints Umesh Sripad as Chief Technology Officer	AQ
18/05	LifeMD to Participate in Upcoming Investor Conferences	AQ
15/05	LifeMD to Participate in Upcoming Investor Conferences	AQ
06/05	LifeMD Reports First Quarter 2026 Results	AQ
27/04	LifeMD to Report First Quarter 2026 Financial Results on May 6	AQ
13/04	LifeMD(R) Now Offering Eli Lilly and Company's Foundayo (orforglipron), a New GLP-1 Pill for Weight Management	AQ
10/04	LifeMD® Now Offering Eli Lilly and Company’s Foundayo™ (orforglipron), a New GLP-1 Pill for Weight Management	AQ
01/04	LifeMD Offers Novo Nordisk's Industry-First Wegovy Telehealth Subscription Program	AQ
31/03	LifeMD Offers Novo Nordisk's Industry-First Wegovy® Telehealth Subscription Program	AQ
24/03	LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock	AQ
16/03	LifeMD Appoints Veteran Healthcare Finance Executive as Chief Financial Officer and Expands Leadership Team	AQ
09/03	LifeMD Reports Fourth Quarter and Full Year 2025 Results	AQ
03/03	LifeMD to Participate in Two Investor Conferences During March	AQ
23/02	LifeMD to Report Fourth Quarter 2025 Financial Results on March 9	AQ
22/01	Kuehn Law Encourages Investors of LifeMD, Inc. to Contact Law Firm	NE
06/01	LifeMD Announces Closing of $50 Million Revolving Credit Facility with Citizens Bank, N.A.	AQ
05/01	LifeMD Expands Collaboration with Novo Nordisk as Recognized Telehealth Partner Offering Newly Approved Wegovy® Pill	AQ
26/12	LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock	AQ
25/11	LifeMD Recognized by the 2025 Deloitte Technology Fast 500 and by TIME's America's Growth Leaders of 2026	AQ
24/11	LifeMD Recognized by the 2025 Deloitte Technology Fast 500™ and by TIME’s America’s Growth Leaders of 2026	AQ
17/11	LifeMD Reports Third Quarter 2025 Results	AQ
17/11	LifeMD® to Offer Market-Leading Pricing for GLP-1 Medications Wegovy® and Ozempic® in Continued Collaboration with Novo Nordisk	AQ